Last reviewed · How we verify
stavudine extended-release, lamivudine, efavirenz
stavudine extended-release, lamivudine, efavirenz is a NRTI and NNRTI combination Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.
Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site.
Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site. Used for Treatment of HIV-1 infection in adults and children, Prevention of HIV-1 infection in adults and children.
At a glance
| Generic name | stavudine extended-release, lamivudine, efavirenz |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | NRTI and NNRTI combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication by blocking the HIV reverse transcriptase enzyme. Lamivudine is also an NRTI that targets the HIV reverse transcriptase enzyme. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to the HIV reverse transcriptase enzyme and blocks its activity, preventing viral replication.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of HIV-1 infection in adults and children
Common side effects
- Nausea
- Headache
- Fatigue
- Dizziness
- Insomnia
Key clinical trials
- Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients (PHASE3)
- DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy (PHASE4)
- Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) (PHASE3)
- Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stavudine extended-release, lamivudine, efavirenz CI brief — competitive landscape report
- stavudine extended-release, lamivudine, efavirenz updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about stavudine extended-release, lamivudine, efavirenz
What is stavudine extended-release, lamivudine, efavirenz?
How does stavudine extended-release, lamivudine, efavirenz work?
What is stavudine extended-release, lamivudine, efavirenz used for?
Who makes stavudine extended-release, lamivudine, efavirenz?
What drug class is stavudine extended-release, lamivudine, efavirenz in?
What development phase is stavudine extended-release, lamivudine, efavirenz in?
What are the side effects of stavudine extended-release, lamivudine, efavirenz?
What does stavudine extended-release, lamivudine, efavirenz target?
Related
- Drug class: All NRTI and NNRTI combination drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Indication: Drugs for Prevention of HIV-1 infection in adults and children
- Compare: stavudine extended-release, lamivudine, efavirenz vs similar drugs
- Pricing: stavudine extended-release, lamivudine, efavirenz cost, discount & access